Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 17Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Cholangiocarcinoma 2Biliary Tract Neoplasms 2Pancreatic Ductal Adenocarcinoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Lymphoma, Follicular 1Leukemia 1IDH1 Mutation Myeloid Neoplasms 1Hematologic Neoplasms 1Glioma 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1AML 1

Interventions

Cyclophosphamide 21Cytarabine 15blinatumomab 13fludarabine 12Azacitidine 10venetoclax 9fludarabine phosphate 9Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Rituximab 6Mercaptopurine 6Daunorubicin 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Etoposide 4Busulfan 4obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm, Residual × ivosidenib × Clear all
NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
120 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡